CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

With a $2.47 million gift from Novo Nordisk Inc., Live HealthSmart Alabama is applying its holistic health model in Selma, ...

We recently compiled a list of the 8 Best Socially Responsible Stocks to Buy According to Hedge Funds. In this article, we ...

How might Medicare price negotiations impact Novo Nordisk's battle in the marketplace with Eli Lilly? Lilly's type 2 diabetes drug Mounjaro and obesity drug Zepbound aren't eligible for Medicare ...

Novo Nordisk is facing serious pressure from a ... thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity. For the company to continue to grow at the ...

Ironically, Ozempic and Wegovy, as with many of Novo Nordisk’s other products, were created primarily for treating diabetes. The weight-loss factor has become a very profitable and unintended ...

Novo Nordisk (NVO) announced Friday that its popular ... The trial involving more than 1,400 obese adults without diabetes reached its primary endpoint as semaglutide 7.2 mg caused a statistically ...

Medicare’s next drug price negotiations will treat Novo Nordisk’s semaglutide as a single product, regardless of whether the metabolic disease medicine is used to treat diabetes or heart risk, and ...

Novo Nordisk has been able to capitalize from a sad trend as the global diabetes patients have quadrupled from 1990 to 2024. Experts expect this trend to continue as they predict another increase ...